Ameriprise Financial Inc. Sells 6,117 Shares of LivaNova PLC (NASDAQ:LIVN)

Ameriprise Financial Inc. trimmed its position in LivaNova PLC (NASDAQ:LIVN - Free Report) by 0.6% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,047,921 shares of the company's stock after selling 6,117 shares during the period. Ameriprise Financial Inc. owned 1.93% of LivaNova worth $48,529,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Russell Investments Group Ltd. boosted its holdings in LivaNova by 17.1% in the 4th quarter. Russell Investments Group Ltd. now owns 1,502 shares of the company's stock valued at $70,000 after purchasing an additional 219 shares during the period. Sterling Capital Management LLC lifted its holdings in shares of LivaNova by 800.6% during the 4th quarter. Sterling Capital Management LLC now owns 1,621 shares of the company's stock worth $75,000 after acquiring an additional 1,441 shares during the last quarter. Vestcor Inc bought a new stake in shares of LivaNova during the 4th quarter worth $204,000. Optimize Financial Inc bought a new stake in shares of LivaNova during the 4th quarter worth $208,000. Finally, Inceptionr LLC bought a new stake in shares of LivaNova during the 4th quarter worth $217,000. 97.64% of the stock is owned by institutional investors.

LivaNova Stock Performance

NASDAQ LIVN opened at $44.06 on Monday. The company has a 50-day simple moving average of $37.89 and a two-hundred day simple moving average of $45.09. The company has a quick ratio of 2.87, a current ratio of 3.37 and a debt-to-equity ratio of 0.46. LivaNova PLC has a 12-month low of $32.48 and a 12-month high of $63.57. The firm has a market cap of $2.40 billion, a price-to-earnings ratio of 104.90 and a beta of 0.84.

Analysts Set New Price Targets

A number of analysts have recently issued reports on LIVN shares. Stifel Nicolaus dropped their price objective on shares of LivaNova from $72.00 to $60.00 and set a "buy" rating for the company in a report on Wednesday, February 26th. StockNews.com downgraded shares of LivaNova from a "strong-buy" rating to a "buy" rating in a report on Thursday. The Goldman Sachs Group dropped their price objective on shares of LivaNova from $64.00 to $55.00 and set a "buy" rating for the company in a report on Monday, March 3rd. Robert W. Baird lifted their price objective on shares of LivaNova from $55.00 to $61.00 and gave the stock an "outperform" rating in a report on Thursday. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $64.00 price objective on shares of LivaNova in a report on Monday, March 17th. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $59.17.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.